[{"address1": "One Amgen Center Drive", "city": "Thousand Oaks", "state": "CA", "zip": "91320-1799", "country": "United States", "phone": "805 447 1000", "fax": "805 447 1010", "website": "https://www.amgen.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.", "fullTimeEmployees": 28000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert A. Bradway", "age": 61, "title": "Chairman, CEO & President", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 6428574, "exercisedValue": 0, "unexercisedValue": 50993104}, {"maxAge": 1, "name": "Mr. Peter H. Griffith", "age": 65, "title": "Executive VP & CFO", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 3007214, "exercisedValue": 0, "unexercisedValue": 1401880}, {"maxAge": 1, "name": "Dr. David M. Reese M.D.", "age": 61, "title": "Executive VP & CTO", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 3327225, "exercisedValue": 0, "unexercisedValue": 7193319}, {"maxAge": 1, "name": "Mr. Murdo  Gordon", "age": 57, "title": "Executive Vice President of Global Commercial Operations", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 3174030, "exercisedValue": 0, "unexercisedValue": 4835902}, {"maxAge": 1, "name": "Dr. James E. Bradner M.D.", "age": 52, "title": "Executive Vice President of Research & Development", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 4095677, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Esteban  Santos", "age": 56, "title": "Executive Vice President of Operations", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 3006074, "exercisedValue": 0, "unexercisedValue": 12988893}, {"maxAge": 1, "name": "Mr. Matthew C. Busch", "age": 49, "title": "Chief Accounting Officer & VP of Finance", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Skellenger", "title": "Senior VP & Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard Y. Chang M.D., Ph.D.", "title": "Senior VP of Global Research & Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Casey  Capparelli", "title": "Executive Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 5, "shareHolderRightsRisk": 2, "overallRisk": 4, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-IRHome", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 333.69, "open": 335.75, "dayLow": 334.74, "dayHigh": 342.84, "regularMarketPreviousClose": 333.69, "regularMarketOpen": 335.75, "regularMarketDayLow": 334.74, "regularMarketDayHigh": 342.84, "dividendRate": 9.52, "dividendYield": 2.82, "exDividendDate": 1763683200, "payoutRatio": 0.72620004, "fiveYearAvgDividendYield": 3.07, "beta": 0.461, "trailingPE": 26.105183, "forwardPE": 16.329947, "volume": 4082766, "regularMarketVolume": 4082766, "averageVolume": 2506214, "averageVolume10days": 2926180, "averageDailyVolume10Day": 2926180, "bid": 337.09, "ask": 337.75, "bidSize": 1, "askSize": 1, "marketCap": 181758754816, "fiftyTwoWeekLow": 253.3, "fiftyTwoWeekHigh": 345.84, "allTimeHigh": 346.85, "allTimeLow": 0.075521, "priceToSalesTrailing12Months": 5.052925, "fiftyDayAverage": 299.77, "twoHundredDayAverage": 294.51074, "trailingAnnualDividendRate": 9.39, "trailingAnnualDividendYield": 0.028139891, "currency": "USD", "tradeable": false, "enterpriseValue": 226900770816, "profitMargins": 0.19474001, "floatShares": 537123700, "sharesOutstanding": 538480671, "sharesShort": 13428043, "sharesShortPriorMonth": 12909801, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.0249, "heldPercentInsiders": 0.00212, "heldPercentInstitutions": 0.83845, "shortRatio": 6.11, "shortPercentOfFloat": 0.025, "impliedSharesOutstanding": 538480671, "bookValue": 17.863, "priceToBook": 18.896042, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "earningsQuarterlyGrowth": 0.136, "netIncomeToCommon": 7005000192, "trailingEps": 12.93, "forwardEps": 20.67, "lastSplitFactor": "2:1", "lastSplitDate": 943228800, "enterpriseToRevenue": 6.308, "enterpriseToEbitda": 13.767, "52WeekChange": 0.14309525, "SandP52WeekChange": 0.09209216, "lastDividendValue": 2.38, "lastDividendDate": 1763683200, "quoteType": "EQUITY", "currentPrice": 337.54, "targetHighPrice": 400.0, "targetLowPrice": 180.0, "targetMeanPrice": 319.57153, "targetMedianPrice": 316.0, "recommendationMean": 2.3871, "recommendationKey": "buy", "numberOfAnalystOpinions": 26, "totalCash": 9445000192, "totalCashPerShare": 17.54, "ebitda": 16481000448, "totalDebt": 54586998784, "quickRatio": 0.823, "currentRatio": 1.28, "totalRevenue": 35970998272, "debtToEquity": 567.491, "revenuePerShare": 66.892, "returnOnAssets": 0.07706, "returnOnEquity": 0.8171, "grossProfits": 25198000128, "freeCashflow": 11408624640, "operatingCashflow": 13125999616, "earningsGrowth": 0.136, "revenueGrowth": 0.124, "grossMargins": 0.70051, "ebitdaMargins": 0.45817003, "operatingMargins": 0.34153, "financialCurrency": "USD", "symbol": "AMGN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "priceEpsCurrentYear": 15.890374, "fiftyDayAverageChange": 37.77002, "fiftyDayAverageChangePercent": 0.12599666, "twoHundredDayAverageChange": 43.029266, "twoHundredDayAverageChangePercent": 0.14610423, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.4 - Buy", "regularMarketChangePercent": 1.15377, "regularMarketPrice": 337.54, "longName": "Amgen Inc.", "marketState": "CLOSED", "gmtOffSetMilliseconds": -18000000, "esgPopulated": false, "cryptoTradeable": false, "shortName": "Amgen Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 424704600000, "postMarketChangePercent": 0.06517782, "postMarketPrice": 337.76, "postMarketChange": 0.22000122, "regularMarketChange": 3.85001, "regularMarketDayRange": "334.74 - 342.84", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2506214, "fiftyTwoWeekLowChange": 84.240005, "fiftyTwoWeekLowChangePercent": 0.3325701, "fiftyTwoWeekRange": "253.3 - 345.84", "fiftyTwoWeekHighChange": -8.299988, "fiftyTwoWeekHighChangePercent": -0.023999503, "fiftyTwoWeekChangePercent": 14.3095255, "dividendDate": 1765497600, "earningsTimestamp": 1762290000, "earningsTimestampStart": 1770152400, "earningsTimestampEnd": 1770152400, "earningsCallTimestampStart": 1762291800, "earningsCallTimestampEnd": 1762291800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 12.93, "epsForward": 20.67, "epsCurrentYear": 21.24179, "corporateActions": [{"header": "Dividend", "message": "AMGN announced a cash dividend of 2.38 with an ex-date of Nov. 21, 2025", "meta": {"eventType": "DIVIDEND", "dateEpochMs": 1763701200000, "amount": "2.38"}}], "postMarketTime": 1763772781, "regularMarketTime": 1763758802, "exchange": "NMS", "messageBoardId": "finmb_24816", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "market": "us_market", "displayName": "Amgen", "trailingPegRatio": 1.0566, "__fetch_time": "2025-11-22"}]